Many studies have demonstrated higher expression of PD-L1 in ALN lesions than in PT in cases of triple-negative BC correlating with high grade and decreased DFS (e.g., 49, 50); these observations played a role in the approval of a pembrolizumab-based anti-PD-L1 treatment for PD-L1-positive advanced BCs (21). The gene discussed is CD274; the disease is breast cancer.